

# Hans-Georg Rammensee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7953826/publications.pdf>

Version: 2024-02-01

166  
papers

16,478  
citations

36303

51  
h-index

16650

123  
g-index

181  
all docs

181  
docs citations

181  
times ranked

17082  
citing authors

#	ARTICLE	IF	CITATIONS
1	A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. <i>Nature</i> , 2022, 601, 617-622.	27.8	153
2	Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues. <i>IScience</i> , 2022, 25, 103768.	4.1	16
3	Identification of tumor antigens for T-cell-mediated cancer immunotherapy. , 2022, , 85-96.		0
4	Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model. <i>Cancers</i> , 2022, 14, 1158.	3.7	6
5	Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 171.	5.4	13
6	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2555-2566.	7.0	31
7	HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients. <i>Cancers</i> , 2022, 14, 2260.	3.7	5
8	Abstract CT258: Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency. <i>Cancer Research</i> , 2022, 82, CT258-CT258.	0.9	3
9	Abstract 3555: Immunopeptidomics-guided tumor antigen warehouse design for peptide-based immunotherapy in head and neck squamous cell carcinomas. <i>Cancer Research</i> , 2022, 82, 3555-3555.	0.9	0
10	Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome. <i>Journal of Proteome Research</i> , 2021, 20, 289-304.	3.7	32
11	SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. <i>Nature Immunology</i> , 2021, 22, 74-85.	14.5	490
12	The Peptide Vaccine of the Future. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100022.	3.8	94
13	Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. <i>Nature Communications</i> , 2021, 12, 1152.	12.8	71
14	Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1907-1919.	1.3	1
15	Integrin Activation Enables Sensitive Detection of Functional CD4+ and CD8+ T Cells: Application to Characterize SARS-CoV-2 Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 626308.	4.8	5
16	Deoxyribonuclease 1-Mediated Clearance of Circulating Chromatin Prevents From Immune Cell Activation and Pro-inflammatory Cytokine Production, a Phenomenon Amplified by Low Trap1 Activity: Consequences for Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021, 12, 613597.	4.8	8
17	Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups. <i>Vaccines</i> , 2021, 9, 428.	4.4	22
18	T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	128

#	ARTICLE	IF	CITATIONS
19	The dominantly expressed class II molecule from a resistant MHC haplotype presents only a few Marek's disease virus peptides by using an unprecedented binding motif. <i>PLoS Biology</i> , 2021, 19, e3001057.	5.6	14
20	HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. , 2021, 9, e002071.		126
21	Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. <i>Cancer Discovery</i> , 2021, 11, 1982-1995.	9.4	34
22	Mass spectrometry for quality control of bispecific antibodies after SDS-PAGE in-gel digestion. <i>Biotechnology and Bioengineering</i> , 2021, 118, 3069-3075.	3.3	3
23	Argyris F Treatment-Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma. <i>Advanced Therapeutics</i> , 2021, 4, 2100078.	3.2	7
24	Broad and Efficient Activation of Memory CD4+ T Cells by Novel HAdV- and HCMV-Derived Peptide Pools. <i>Frontiers in Immunology</i> , 2021, 12, 700438.	4.8	2
25	Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 705974.	4.8	22
26	SARS-CoV-2-reactive T cell receptors isolated from convalescent COVID-19 patients confer potent T cell effector function. <i>European Journal of Immunology</i> , 2021, 51, 2651-2664.	2.9	9
27	Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors. , 2021, 9, e003404.		11
28	An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e11902.	6.9	28
29	Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. <i>OncImmunology</i> , 2021, 10, 2006893.	4.6	4
30	HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. <i>Cell</i> , 2020, 183, 1264-1281.e20.	28.9	133
31	Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. , 2020, 8, e001157.		28
32	HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Cancers</i> , 2020, 12, 1835.	3.7	18
33	Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	13
34	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 595-610.	27.6	124
35	Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 24.	6.2	15
36	Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 432-443.	3.8	31

#	ARTICLE	IF	CITATIONS
37	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. <i>Genome Medicine</i> , 2020, 12, 32.	8.2	32
38	The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3128-3128.	1.6	1
39	The Impact of Biomaterial Cell Contact on the Immuno-peptidome. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 571294.	4.1	5
40	High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules. <i>Science Immunology</i> , 2019, 4, .	11.9	35
41	MHCquant: Automated and Reproducible Data Analysis for Immuno-peptidomics. <i>Journal of Proteome Research</i> , 2019, 18, 3876-3884.	3.7	35
42	PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2019, 7, 1891-1899.	3.4	66
43	A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. , 2019, 7, 307.		39
44	Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1949-1958.	4.2	24
45	Human CCR5 <sup>high</sup> effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. <i>Brain</i> , 2019, 142, 3411-3427.	7.6	39
46	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1255-1268.	3.8	45
47	Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. <i>Genome Medicine</i> , 2019, 11, 28.	8.2	107
48	G $\beta$ s-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells. <i>Journal of Experimental Medicine</i> , 2019, 216, 517-526.	8.5	45
49	Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immuno-peptidome in Glioblastoma. <i>Molecular Therapy - Oncolytics</i> , 2019, 12, 147-161.	4.4	38
50	The administration route of tumor-antigen-specific T-helper cells differentially modulates the tumor microenvironment and senescence. <i>Carcinogenesis</i> , 2019, 40, 289-302.	2.8	4
51	A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2526.	4.8	29
52	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	27.8	637
53	Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome. <i>Immunogenetics</i> , 2019, 71, 203-216.	2.4	12
54	The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. <i>Blood</i> , 2019, 133, 550-565.	1.4	57

#	ARTICLE	IF	CITATIONS
55	Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases. <i>European Urology Focus</i> , 2019, 5, 604-607.	3.1	17
56	Abstract B124: Personalized peptide vaccination based on patient-individual tumor-specific variants induces T-cell responses in pediatric patients. <i>Cancer Immunology Research</i> , 2019, 7, B124-B124.	3.4	1
57	Targeting tumor-resident mast cells for effective anti-melanoma immune responses. <i>JCI Insight</i> , 2019, 4, .	5.0	36
58	Personalized cancer vaccines: adjuvants are important, too. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1911-1918.	4.2	44
59	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028829.	5.5	40
60	Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. <i>Leukemia and Lymphoma</i> , 2018, 59, 1949-1958.	1.3	4
61	The SysteMHC Atlas project. <i>Nucleic Acids Research</i> , 2018, 46, D1237-D1247.	14.5	119
62	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. <i>Acta Neuropathologica</i> , 2018, 135, 923-938.	7.7	36
63	Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA Peptide Multimer Staining Assay. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 342-353.	1.5	12
64	HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. <i>Onc Immunology</i> , 2018, 7, e1316438.	4.6	42
65	IMMU-28. DECIPHERING THE AT/RT LIGANDOME. <i>Neuro-Oncology</i> , 2018, 20, i104-i104.	1.2	0
66	Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. <i>Cancer Research</i> , 2018, 78, 4627-4641.	0.9	56
67	Activated integrins identify functional antigen-specific CD8 <sup>+</sup> T cells within minutes after antigen stimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5536-E5545.	7.1	19
68	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2132-2145.	3.8	41
69	First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications. <i>BMC Medical Genetics</i> , 2018, 19, 144.	2.1	5
70	Identification of non-mutated neoantigens presented by TAP-deficient tumors. <i>Journal of Experimental Medicine</i> , 2018, 215, 2325-2337.	8.5	64
71	A tissue-based draft map of the murine MHC class I immunopeptidome. <i>Scientific Data</i> , 2018, 5, 180157.	5.3	45
72	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2000-2000.	1.6	17

#	ARTICLE	IF	CITATIONS
73	HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3135-TPS3135.	1.6	7
74	Mass Spectrometry-Based Immunopeptidome Analysis of Acute Myeloid Leukemia Cells Under Decitabine Treatment Delineates Induced Presentation of Cancer/Testis Antigens on HLA Class I Molecules. <i>Blood</i> , 2018, 132, 5223-5223.	1.4	0
75	Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols. <i>Annals of Surgical Oncology</i> , 2017, 24, 1650-1657.	1.5	11
76	Identification of Immunogenic Epitopes by MS/MS. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 102-107.	2.0	19
77	HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. <i>Oncolmmunology</i> , 2017, 6, e1219825.	4.6	28
78	The European Regulatory Environment of RNA-Based Vaccines. <i>Methods in Molecular Biology</i> , 2017, 1499, 203-222.	0.9	22
79	NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 755.	12.8	38
80	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017, 280, 165-174.	6.0	82
81	Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8 <sup>+</sup> cytotoxic T cells. <i>Haematologica</i> , 2017, 102, e460-e464.	3.5	7
82	Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices. <i>Journal of Immunology</i> , 2017, 199, 2639-2651.	0.8	81
83	The immunopeptidomic landscape of ovarian carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9942-E9951.	7.1	152
84	A Simple and Rapid Method for Quality Control of Major Histocompatibility Complex“Peptide Monomers by Flow Cytometry. <i>Frontiers in Immunology</i> , 2017, 8, 96.	4.8	4
85	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and “pan-leukemia“antigens. <i>Oncotarget</i> , 2017, 8, 43915-43924.	1.8	12
86	Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody. <i>Molecular Therapy</i> , 2016, 24, 1634-1643.	8.2	18
87	Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. <i>Journal of Hepatology</i> , 2016, 65, 849-855.	3.7	75
88	Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design. <i>Oncolmmunology</i> , 2016, 5, e1204504.	4.6	19
89	HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1065369.	4.6	18
90	A Recombinant Bispecific CD20–CD95 Antibody With Superior Activity Against Normal and Malignant B-cells. <i>Molecular Therapy</i> , 2016, 24, 298-305.	8.2	6

#	ARTICLE	IF	CITATIONS
91	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. <i>OncImmunology</i> , 2016, 5, e1108511.	4.6	41
92	Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. <i>PLoS ONE</i> , 2016, 11, e0167017.	2.5	17
93	Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8+ and CD4+ T Cell-Epitopes for Immunotherapeutic Approaches. <i>Blood</i> , 2016, 128, 4232-4232.	1.4	1
94	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. <i>Blood</i> , 2015, 126, 1203-1213.	1.4	103
95	Innate immune system favors emergency monopoiesis at the expense of DC differentiation to control systemic bacterial infection in mice. <i>European Journal of Immunology</i> , 2015, 45, 2821-2833.	2.9	24
96	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. <i>PLoS ONE</i> , 2015, 10, e0140483.	2.5	13
97	<sup>64</sup> Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1161-1166.	7.1	65
98	Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia. <i>Molecular Therapy</i> , 2015, 23, 648-655.	8.2	48
99	HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E166-75.	7.1	150
100	Antileukemia T-cell responses in CLL – We don't need no aberration. <i>OncImmunology</i> , 2015, 4, e1011527.	4.6	15
101	Dipeptides catalyze rapid peptide exchange on MHC class I molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 202-207.	7.1	45
102	An open-source computational and data resource to analyze digital maps of immunopeptidomes. <i>ELife</i> , 2015, 4, .	6.0	107
103	Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers. <i>Blood</i> , 2015, 126, 1722-1722.	1.4	0
104	Human Peripheral CD4+ V $\alpha$ 1+ $\gamma$ $\delta$ T Cells Can Develop into $\gamma$ $\delta$ T Cells. <i>Frontiers in Immunology</i> , 2014, 5, 645.	4.8	40
105	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014, 515, 577-581.	27.8	1,705
106	An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. <i>Journal of Immunological Methods</i> , 2014, 405, 192-198.	1.4	59
107	Cutaneous Innate Immune Sensing of Toll-like Receptor 2-6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells. <i>Immunity</i> , 2014, 41, 762-775.	14.3	119
108	TLR9 independent interferon $\gamma$ production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2199-2207.	0.9	83

#	ARTICLE	IF	CITATIONS
109	Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia (CML)â€”Towards Peptide Based Immunotherapy. <i>Blood</i> , 2014, 124, 4518-4518.	1.4	1
110	Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. , 2013, 1, 11.		56
111	Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1485-1497.	4.2	22
112	The regulatory landscape for actively personalized cancer immunotherapies. <i>Nature Biotechnology</i> , 2013, 31, 880-882.	17.5	62
113	HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. <i>Brain</i> , 2013, 136, 1783-1798.	7.6	40
114	HLA ligandome tumor antigen discovery for personalized vaccine approach. <i>Expert Review of Vaccines</i> , 2013, 12, 1211-1217.	4.4	87
115	Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons. <i>Nature Communications</i> , 2013, 4, 1616.	12.8	81
116	In vitro effect of molluscan hemocyanins on CAL-29 and T-24 bladder cancer cell lines. <i>Biomedical Reports</i> , 2013, 1, 235-238.	2.0	14
117	TLR9-independent and immune complex-independent interferon $\hat{\pm}$ production by neutrophils upon netosis in response to circulating chromatin. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A84.1-A84.	0.9	0
118	Multipptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. <i>Nature Medicine</i> , 2012, 18, 1254-1261.	30.7	721
119	Promiscuous survivin peptide induces robust CD4<sup>+</sup> Tâ€™cell responses in the majority of vaccinated cancer patients. <i>International Journal of Cancer</i> , 2012, 131, 140-149.	5.1	70
120	Identification of Novel Tumor-Associated Antigens for Chronic Lymphocytic Leukemia (CLL) Based On HLA Ligandome Analysis â€™ New Targets for Peptide Based Immunotherapy. <i>Blood</i> , 2012, 120, 4119-4119.	1.4	0
121	Human Peripheral CD34+ $\hat{\pm}$ T Cells Can Transdifferentiate into $\hat{\pm}$ T Cells.. <i>Blood</i> , 2012, 120, 2312-2312.	1.4	0
122	HLA Ligandome Analysis of Acute Myeloid Leukemia (AML) Revealed Novel Tumor-Associated Antigens for Immunotherapy.. <i>Blood</i> , 2012, 120, 3012-3012.	1.4	0
123	Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 581-581.	1.4	6
124	Development of New Autoimmunity Against T Cell Antigens Derived From Retinal Proteins After Allogeneic Hematopoietic Cell Transplantation.. <i>Blood</i> , 2012, 120, 3060-3060.	1.4	0
125	Chromatin-activated neutrophils represent a major source of interferon $\hat{\pm}$ . <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A38-A39.	0.9	1
126	Inhibition of Antibody Production in Vitro with Bispecific CD20 X CD95 Antibodies. <i>Blood</i> , 2011, 118, 1114-1114.	1.4	0



#	ARTICLE	IF	CITATIONS
127	Novel multi-peptide vaccination in HLA-A*02+ hormone sensitive patients with biochemical relapse of prostate cancer. <i>Prostate</i> , 2009, 69, 917-927.	2.3	97
128	Identification of HLA-A*01- and HLA-A*02-restricted CD8+ T-cell epitopes shared among group B enteroviruses. <i>Journal of General Virology</i> , 2008, 89, 2090-2097.	2.9	27
129	Long-Term Immunity against Actual Poxviral HLA Ligands as Identified by Differential Stable Isotope Labeling. <i>Journal of Immunology</i> , 2008, 181, 6371-6383.	0.8	25
130	Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 102-113.	3.8	121
131	Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. <i>Cancer Immunology, Immunotherapy</i> , 2007, 57, 175-183.	4.2	50
132	Peptides Made to Order. <i>Immunity</i> , 2006, 25, 693-695.	14.3	11
133	An Immunogenic Peptide Derived from NM23-H2 Is Expressed on Bcr/abl+ Cells.. <i>Blood</i> , 2006, 108, 3684-3684.	1.4	0
134	Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. <i>Nature Biotechnology</i> , 2004, 22, 450-454.	17.5	82
135	The Tiling approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 187-195.	4.2	132
136	Cutting Edge: Predetermined Avidity of Human CD8 T Cells Expanded on Calibrated MHC/Anti-CD28-Coated Microspheres. <i>Journal of Immunology</i> , 2003, 171, 4974-4978.	0.8	53
137	Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon- $\gamma$ -enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. <i>Blood</i> , 2002, 99, 3830-3837.	1.4	151
138	Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. <i>Blood</i> , 2002, 99, 3916-3922.	1.4	660
139	Towards patient-specific tumor antigen selection for vaccination. <i>Immunological Reviews</i> , 2002, 188, 164-176.	6.0	73
140	Integrated functional genomics approach for the design of patient-individual antitumor vaccines. <i>Cancer Research</i> , 2002, 62, 5818-27.	0.9	161
141	Ligand motif of the autoimmune disease-associated mouse MHC class II molecule H2-As. <i>European Journal of Immunology</i> , 2001, 31, 551-562.	2.9	23
142	Peptides presented by HLA molecules and clinical applications. <i>Biochemical Society Transactions</i> , 2000, 28, A119-A119.	3.4	0
143	Identification of a new HLA-A*0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. <i>International Journal of Cancer</i> , 2000, 87, 399-404.	5.1	45
144	The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. <i>European Journal of Immunology</i> , 2000, 30, 2211-2215.	2.9	287

#	ARTICLE	IF	CITATIONS
145	Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. European Journal of Immunology, 2000, 30, 2216-2225.	2.9	131
146	<i>In vivo</i> application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. European Journal of Immunology, 2000, 30, 1-7.	2.9	331
147	gp96 "The immune system's Swiss army knife. Nature Immunology, 2000, 1, 100-101.	14.5	78
148	Cross-Presentation of Glycoprotein 96 "Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis. Journal of Experimental Medicine, 2000, 191, 1965-1974.	8.5	325
149	<i>In vivo</i> application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. , 2000, 30, 1.		2
150	<i>In vivo</i> application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. , 2000, 30, 1.		2
151	<i>In vivo</i> application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. European Journal of Immunology, 2000, 30, 1-7.	2.9	7
152	Molecular cloning of a macrophage-derived, interferon-inducible secreted immunoglobulin-binding protein. European Journal of Immunology, 1999, 29, 1504-1512.	2.9	2
153	Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. , 1998, 75, 688-693.		17
154	Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire. European Journal of Immunology, 1998, 28, 2432-2443.	2.9	38
155	A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. European Journal of Immunology, 1998, 28, 3301-3311.	2.9	54
156	Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities. European Journal of Immunology, 1998, 28, 4029-4036.	2.9	68
157	The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. European Journal of Immunology, 1997, 27, 923-927.	2.9	111
158	Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human V $\beta$ 9/V $\beta$ 2 T cells in tumor immunity. European Journal of Immunology, 1997, 27, 3368-3379.	2.9	115
159	Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation. European Journal of Immunology, 1996, 26, 875-879.	2.9	25
160	The peptide binding motif of the disease associated HLA-DQ ( $\beta$ 1* 0501, $\beta$ 2* 0201) molecule. European Journal of Immunology, 1996, 26, 2764-2772.	2.9	154
161	MHC ligands and peptide motifs: first listing. Immunogenetics, 1995, 41, 178-228.	2.4	1,606
162	Chemistry of peptides associated with MHC class I and class II molecules. Current Opinion in Immunology, 1995, 7, 85-96.	5.5	336

#	ARTICLE	IF	CITATIONS
163	Self Tolerance of Natural MHC Class I Ligands. <i>International Reviews of Immunology</i> , 1993, 10, 291-300.	3.3	7
164	MHC Class I-Restricted Antigen Processing – Lessons from Natural Ligands. <i>Chemical Immunology and Allergy</i> , 1993, 57, 113-133.	1.7	6
165	Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. <i>Nature</i> , 1991, 351, 290-296.	27.8	2,407
166	In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. <i>Nature</i> , 1989, 342, 561-564.	27.8	655